SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Vanda Pharmaceuticals, Inc. engages in the development and commercialization of therapies for high unmet medical needs. The firm intends to treat schizophrenia, jet lag disorder, atopic dermatitis, central nervous system disorders, and circadian rhythm sleep disorder. Its product portfolio includes HETLIOZ, Fanapt, Tradipitant, Trichostatin, and AQW051. The company was founded by Mihael Hristos Polymeropoulos and Argeris N. Karabelas in 2002 and is headquartered in Washington, DC.

Vanda Pharmaceuticals Inc

Vanda Pharmaceuticals is trending after an FDA Complete Response Letter for its jet lag drug, but community discussion has quickly pivoted to intense anticipation for the upcoming February 21st PDUFA decision for Bysanti. Many investors expect Bysanti's approval to be a major re-rating catalyst, compounded by ongoing speculation about a significant buyout driven by the 'mega blockbuster' potential of Tradipitant for GLP-1-induced nausea.

NIO, Inc. is a holding company which engages in the design, manufacture, and sale of electric vehicles. Its products include the EP9 supercar and ES8 7-seater SUV. It provides users with home charging, power express valet services, and other power solutions including access to public charging, access to power mobile charging trucks, and battery swapping. It also offers other value-added services such as service package, battery payment arrangement, and vehicle financing and license plate registration. The company was founded by Bin Li and Li Hong Qin on November 28, 2014 and is headquartered in Jiading, China.

NIO Inc - ADR

NIO Inc

NIO is sparking significant investor conversation as the stocks recent upward movement past a crucial price point, following options expiration, has ignited hopes for a substantial rally. The bullish sentiment is amplified by continuous record-breaking battery swaps, bolstering confidence in the companys unique ecosystem and upcoming profitability report.

CrowdStrike Holdings, Inc. provides cybersecurity products and services to stop breaches. It offers cloud-delivered protection across endpoints, cloud workloads, identity and data, and threat intelligence, managed security services, IT operations management, threat hunting, Zero Trust identity protection, and log management. CrowdStrike serves customers worldwide. The company was founded by George P. Kurtz, Gregg Marston, and Dmitri Alperovitch on November 7, 2011 and is headquartered in Austin, TX.

Crowdstrike Holdings Inc - Ordinary Shares - Class A

Crowdstrike Holdings Inc

CrowdStrike is trending due to a cybersecurity sector sell-off, triggered by concerns that Anthropic's new Claude Code Security tool, capable of finding software vulnerabilities, will intensify competition. However, many in the community argue this reaction is overblown, asserting that Claude's code analysis capabilities do not directly compete with CrowdStrike's core runtime and endpoint protection offerings.

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+ and TMTG News. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

Trump Media (DJT) is trending as the Supreme Court's ruling against the administration's tariffs, potentially triggering billions in refunds, sparks intense debate, even as the administration swiftly vows to implement new trade actions.

Tonix Pharmaceuticals Holding Corp. is a clinical-stage biopharmaceutical company, which focuses on the discovery, acquisition, and development of small molecules and biologics to treat and prevent human disease and alleviate suffering. Its portfolio includes TNX-102 SL, TNX-601, TNX-801, and TNX-1800. The company was founded by Seth Lederman and Donald W. Landry on November 16, 2007 and is headquartered in Berkeley Heights, NJ.

Tonix Pharmaceuticals Holding Corp

Tonix Pharmaceuticals is trending as preliminary financial results reveal strong initial sales for its newly launched fibromyalgia drug, TONMYA, surpassing expectations and fueling a bullish narrative among investors who highlight increasing institutional ownership and the drug's growing market access amidst a broader shift towards non-opioid therapies.

🔥 COCK Token – The Ultimate Cross-Chain MemeFi Powerhouse 🔥  In just under 20 days, $COCK has smashed expectations, broken ATHs, and built a project that’s shaking up Cardano and the entire crypto space. 🐓 What Makes $COCK Special?      The Name: Love it or hate it, the energy and engagement it generates are undeniable. The nuance in language and wild appeal set us apart.     #MEMEFI Pioneer: We’re not just another meme coin. $COCK is leading a movement by combining DeFi mechanics, game theory, and community engagement into a groundbreaking ecosystem.     COCKARENA: At the core of our ecosystem is the COCKARENA, a PvP HODL game. Players battle it out, and early exit fees fuel redistributions, burns, and the treasury. This ensures price appreciation and long-term sustainability for loyal holders.  🎰 The COCK Casino  Our casino isn’t just fun—it’s a serious revenue stream for the FLOCK.      Games: Bonanza, Crash, Blackjack, and Roulette (coming soon!).     Impact: Over 7,834 ADA in profits generated within days, directly supporting rewards, burns, and reinvestment.  💰 COCK-ARENA Loans  Unlock liquidity without selling your tokens.      Loan Terms: Borrow up to 30% of your holdings while continuing to earn rewards in the arena.     Investor Focus: Perfect for savvy investors staying in the game while tapping into their holdings.  🤝 Our Insane Partnerships  We’re bridging gaps, building alliances, and breaking barriers across the crypto space. Key Partners:      DANZO: Powering #MEMEFI with Arena, Casino, and Loans.     KLENEK: Interactive training room.     HSKN (Charles Hoskilien): Supporting and starting COCKPIN with 115 AIR NODES for DePIN aggregation. Plans to add APEX and Earth Nodes through a crypto company incorporated in Costa Rica.     ELITE CATS / SNEKKIES / HOT / BANK: Rewarding NFT holders with COCK-LOCK tokens and vice versa.     OCKZ: COCKSOCKS, Golden Cock Ticket (1M COCK), airdrop rewards, and whitelist perks for holders of 200 ADA worth of $COCK.     OLI Partnership:         Content Creation: Lux and the team are crafting engaging educational content about memes and MemeFi for OLi's platform.         Strategic Investment: The OLi Community Trust will invest in $COCK, distributing 100% of rewards to $OLI holders.         Community Reach: Over 22,000 learners will discover $COCK through OLi's gamified ecosystem.     Hi-Rez the Rapper: Expanding reach in marketing and entertainment.     KUNO, CALEB, CADEN, FITY, ROVER, WhaleInsider: Influential collaborators driving crypto adoption and growth.     Cardano Girls: Helping us understand and communicate effectively with ADA’s female audience.     WallStreetBets: Breaking barriers and increasing engagement.     Antonio Brown: Endorsing, supporting, and even playing in the casino and arena!     Advisors:         BERIS, HECKTHESNEK, RTB, CRYPTOGENIUS: Trusted names advising and supporting the project.  Future Partnerships:  More collaborations are in the pipeline to continue expanding engagement and bring new eyes to ADA and CNTs. 🔥 Unmatched Results in Just 20 Days      Supply Burned: 1.65%, worth 148K ADA!     Arena Fees Collected: 54M COCK, worth over 500K ADA, fueling rewards, burns, and partnerships.     Staked COCK-LOCK: 11M COCK-LOCK in the liquid staking platform, with more coming.     Casino Revenue: Skyrocketing profits directly rewarding holders and growing the treasury.     Top Blast Contests: Generated over 120K ADA in volume, rewarding participants with over 50K ADA in prizes.  🌍 Our Vision  To be the most decentralized, rewarding, and innovative token on Cardano while fostering cross-chain collaboration and onboarding the masses.      Breaking Barriers: We’re bringing BTC, ETH, SOL, and other chains into the fold.     Community-Driven: Focused on building bridges and showcasing that crypto can be fun, rewarding, and sustainable.     Expansion: This is just the beginning. With more burns, rewards, and partnerships on the way, $COCK is set to redefine what’s possible in the MemeFi space.  💎 Time in the arena &gt; Timing the market. The FLOCK is unstoppable. Let’s keep breaking walls for Cardano and onboard new users as we take $COCK to new heights.

CockCardano

COCK CRYPTO is trending within the Cardano ecosystem, fueled by its highly engaged "Flock" community actively promoting the token, its associated Cocky Wings LLC brand, and staking opportunities. The community is buzzing with bullish sentiment, discussing its potential for significant gains and collective strength.

JFrog Ltd. engages in the provision of an end-to-end, hybrid, universal development operations platform that powers and controls the software supply chain, which enables organizations to continuously and securely deliver software updates across any system. It operates through the following geographical segments: United States, Israel, India, and Rest of World. The firm is also involved in creating software delivered without friction from developer to device. The company was founded by Frederic Simon, Shlomi Ben Haim, and Yoav Landman in 2008 and is headquartered in Sunnyvale, CA.

JFrog Ltd

JFrog ($FROG) is actively discussed after its Q4 earnings beat estimates and an announced strategic collaboration with AWS, fueling community optimism about its role in DevSecOps and AI-driven software delivery, with analysts reiterating bullish outlooks.

Moonlake Immunotherapeutics operates as a clinical-stage biotechnology company. It offers tri-specific Nanobody, Sonelokimab to address significant unmet needs in inflammatory skin and joint diseases. The company was founded by Kristian Reich, Jorge Santos da Silva, and Arnout Ploos van Amstel in 2021 and is headquartered in Zug, Switzerland.

MoonLake Immunotherapeutics - Ordinary Shares - Class A

MoonLake Immunotherapeutics

MoonLake Immunotherapeutics is trending as a major fund makes a significant reversal in its positioning, buying back millions of shares at higher prices, ahead of a highly anticipated Investor Day event next week that promises key clinical trial and FDA updates. The community is buzzing with bullish sentiment, anticipating a substantial revaluation, potential short squeeze, or even a buyout, fueled by confidence in its pipeline and the recent institutional accumulation.

OpGen, Inc. is a precision medicine company, which engages in the power of molecular diagnostics and informatics to help combat infectious disease. It focuses on the development of molecular information products and services for global healthcare settings. The firm's also offers guidance to clinicians about life threatening infections, improving patient outcomes, and decreasing the spread of infections caused by multidrug-resistant microorganisms. Its products include Unyvero, Acuitas AMR Gene Panel and Acuitas Lighthouse, and the ARES Technology Platform including ARESdb, using NGS technology and AI-powered bioinformatics solutions for antibiotic response prediction. The company was founded on January 22, 2001 and is headquartered in Clarksburg, MD.

Opgen Inc

OPGN is trending amid strong community anticipation for its upcoming shareholder meeting, where a critical name change to CapForce is expected, solidifying its strategic pivot into an AI-enabled fintech platform. Investors are keenly discussing the potential for a swift NASDAQ relisting and substantial upside, supported by major backing from AEI Capital and its network, despite recent volatility stemming from low trading volume.

NIKE, Inc. engages in the design, development, marketing, and sale of athletic footwear, apparel, accessories, equipment, and services. It operates through the following segments: North America, Europe, Middle East, and Africa (EMEA), Greater China, Asia Pacific and Latin America (APLA), Global Brand Divisions, Converse, and Corporate. The North America, EMEA, Greater China, and APLA segments refer to the design, development, marketing, and selling of athletic footwear, apparel, and equipment. The Global Brand Divisions segment represents its NIKE Brand licensing businesses. The Converse segment designs, markets, licenses, and sells casual sneakers, apparel, and accessories. The Corporate segment is composed of unallocated general and administrative expenses. The company was founded by William Jay Bowerman and Philip Hampson Knight on January 25, 1964 and is headquartered in Beaverton, OR.

Nike, Inc. - Ordinary Shares - Class B

Nike Inc

Nike is trending as community members express confusion and frustration over its unexpected price action following a Supreme Court ruling on tariffs, fueling discussions about market manipulation alongside ongoing concerns about its restructuring efforts and recent layoffs.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Dare Bioscience, Inc. (DARE) Reports Q3 Loss, Lags Revenue Estimates

Dare Bioscience (DARE) delivered earnings and revenue surprises of +15.15% and -95.00%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?

Caribou Biosciences, Inc. (CRBU) Reports Q3 Loss, Misses Revenue Estimates

Caribou Biosciences (CRBU) delivered earnings and revenue surprises of +16.67% and -14.34%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?

Editas Medicine (EDIT) Reports Q3 Loss, Beats Revenue Estimates

Editas (EDIT) delivered earnings and revenue surprises of +26.32% and +365.62%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?

Sutro Biopharma, Inc. (STRO) Reports Q3 Loss, Tops Revenue Estimates

Sutro Biopharma (STRO) delivered earnings and revenue surprises of -59.52% and +16.52%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?

Arcellx, Inc. (ACLX) Reports Q3 Loss, Misses Revenue Estimates

Arcellx (ACLX) delivered earnings and revenue surprises of -3.13% and -66.20%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?

AC Immune (ACIU) Reports Q3 Loss, Lags Revenue Estimates

AC Immune (ACIU) delivered earnings and revenue surprises of +9.09% and -22.51%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?

Dare Bioscience, Inc. (DARE) Reports Q2 Loss, Lags Revenue Estimates

Dare Bioscience (DARE) delivered earnings and revenue surprises of +18.18% and -103.68%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Immatics (IMTX) Reports Q2 Loss, Misses Revenue Estimates

Immatics (IMTX) delivered earnings and revenue surprises of -73.68% and -62.32%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Editas Medicine (EDIT) Reports Q2 Loss, Tops Revenue Estimates

Editas (EDIT) delivered earnings and revenue surprises of -53.66% and +320.94%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

C4 Therapeutics, Inc. (CCCC) Reports Q2 Loss, Misses Revenue Estimates

C4 Therapeutics (CCCC) delivered earnings and revenue surprises of +2.63% and -0.57%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Daré Bioscience, Inc. operates as a healthcare company, which engages in the development and commercialization of pharmaceutical products in women's reproductive health. Its products include Ovaprene and Topical Sildenafil. The company was founded by Sabrina Martucci Johnson, Lisa Walters-Hoffert and Roger L. Hawley on November 28, 2005 and is headquartered in San Diego, CA.

Current Price	$1.65
Prev Close	$1.67
Open	$1.67
Dividend Yield	0.00%
50-Day Moving Average	$1.95
Beta	0.48
Avg. Volume	72,475.00
PE Ratio	-3.78

52-Week High	$9.19
52-Week Low	$1.61
Market Capitalization	$23.86M
EPS (Annual)	-$0.477
Price to Book	8.14
Revenue Per Employee	$425.39

DARE
Dare Bioscience Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest DARE News

DAREDare Bioscience Inc